To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure
BackgroundMineralocorticoid receptor antagonists (MRAs) are pivotal in heart failure (HF) management.ObjectivesThis study evaluates their impact on adverse cardiovascular events and left ventricular ejection fraction (LVEF) in HF patients.MethodsA comprehensive literature search was conducted across...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1564860/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849713914795786240 |
|---|---|
| author | Jinyu He Gang Chen Yujia Huo Chunyu Zhang Haojie Xue Jing Wang Yi Zhong Juan Xiao Hongping Shen Jian Feng Jian Feng |
| author_facet | Jinyu He Gang Chen Yujia Huo Chunyu Zhang Haojie Xue Jing Wang Yi Zhong Juan Xiao Hongping Shen Jian Feng Jian Feng |
| author_sort | Jinyu He |
| collection | DOAJ |
| description | BackgroundMineralocorticoid receptor antagonists (MRAs) are pivotal in heart failure (HF) management.ObjectivesThis study evaluates their impact on adverse cardiovascular events and left ventricular ejection fraction (LVEF) in HF patients.MethodsA comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials databases, with a cutoff date of September 30, 2024. All included studies were randomized controlled trials (RCTs) that recorded the incidence of adverse cardiovascular events and changes in LVEF after MRA treatment in HF patients.ResultsA total of 30 randomized controlled trials involving 24,831 patients with heart failure were included. Compared to conventional therapy or placebo, treatment with MRAs significantly reduced the risk of all-cause mortality (RR = 0.862, 95% CI: 0.778–0.956, p = 0.005; I2 = 36.1%), cardiovascular mortality (RR = 0.828, 95% CI: 0.732–0.937, p = 0.003; I2 = 45.7%), and heart failure-related hospitalization (RR = 0.780, 95% CI: 0.657–0.926, p = 0.005; I2 = 65.5%). Moreover, MRAs significantly improved LVEF (WMD = 1.384, 95% CI: 0.208–2.559, p = 0.021; I2 = 59.9%). However, MRA therapy was associated with an increased risk of renal dysfunction, including hyperkalemia (RR = 2.086, 95% CI: 1.872–2.325, p < 0.001; I2 = 0.0%), elevated serum creatinine (RR = 1.512, 95% CI: 1.252–1.825, p < 0.001; I2 = 0.0%), decreased eGFR (WMD = −5.223, 95% CI: −7.380 to −3.066, p < 0.001; I2 = 0.0%), and potentially increased incidence of composite renal outcomes.ConclusionMRAs significantly reduce the risk of adverse cardiovascular events in patients with heart failure and contribute to LVEF improvement. They lower all-cause mortality in patients with HFrEF and reduce hospitalization for heart failure in those with HFmrEF or HFpEF. However, the potential risk of renal-related adverse events warrants close monitoring.
Our protocol was registered in PROSPERO (registration number: CRD42024592012). |
| format | Article |
| id | doaj-art-ee2525dda4b741df8c19088603eb8aa5 |
| institution | DOAJ |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-ee2525dda4b741df8c19088603eb8aa52025-08-20T03:13:50ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-07-011210.3389/fcvm.2025.15648601564860To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failureJinyu He0Gang Chen1Yujia Huo2Chunyu Zhang3Haojie Xue4Jing Wang5Yi Zhong6Juan Xiao7Hongping Shen8Jian Feng9Jian Feng10Department of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaClinical Pharmacy Office, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Cardiology, The Affiliated Hospital of Southwest Medical University, Luzhou, ChinaDepartment of Cardiology, Southwest Medical University Affiliated Hospital Medical Group Gulin Hospital (Gulin County People’s Hospital), Southwest Medical University, Luzhou, ChinaBackgroundMineralocorticoid receptor antagonists (MRAs) are pivotal in heart failure (HF) management.ObjectivesThis study evaluates their impact on adverse cardiovascular events and left ventricular ejection fraction (LVEF) in HF patients.MethodsA comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials databases, with a cutoff date of September 30, 2024. All included studies were randomized controlled trials (RCTs) that recorded the incidence of adverse cardiovascular events and changes in LVEF after MRA treatment in HF patients.ResultsA total of 30 randomized controlled trials involving 24,831 patients with heart failure were included. Compared to conventional therapy or placebo, treatment with MRAs significantly reduced the risk of all-cause mortality (RR = 0.862, 95% CI: 0.778–0.956, p = 0.005; I2 = 36.1%), cardiovascular mortality (RR = 0.828, 95% CI: 0.732–0.937, p = 0.003; I2 = 45.7%), and heart failure-related hospitalization (RR = 0.780, 95% CI: 0.657–0.926, p = 0.005; I2 = 65.5%). Moreover, MRAs significantly improved LVEF (WMD = 1.384, 95% CI: 0.208–2.559, p = 0.021; I2 = 59.9%). However, MRA therapy was associated with an increased risk of renal dysfunction, including hyperkalemia (RR = 2.086, 95% CI: 1.872–2.325, p < 0.001; I2 = 0.0%), elevated serum creatinine (RR = 1.512, 95% CI: 1.252–1.825, p < 0.001; I2 = 0.0%), decreased eGFR (WMD = −5.223, 95% CI: −7.380 to −3.066, p < 0.001; I2 = 0.0%), and potentially increased incidence of composite renal outcomes.ConclusionMRAs significantly reduce the risk of adverse cardiovascular events in patients with heart failure and contribute to LVEF improvement. They lower all-cause mortality in patients with HFrEF and reduce hospitalization for heart failure in those with HFmrEF or HFpEF. However, the potential risk of renal-related adverse events warrants close monitoring. Our protocol was registered in PROSPERO (registration number: CRD42024592012).https://www.frontiersin.org/articles/10.3389/fcvm.2025.1564860/fullheart failuremineralocorticoid receptor antagonistsall-cause mortalitycardiovascular deathmeta-analysis |
| spellingShingle | Jinyu He Gang Chen Yujia Huo Chunyu Zhang Haojie Xue Jing Wang Yi Zhong Juan Xiao Hongping Shen Jian Feng Jian Feng To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure Frontiers in Cardiovascular Medicine heart failure mineralocorticoid receptor antagonists all-cause mortality cardiovascular death meta-analysis |
| title | To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure |
| title_full | To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure |
| title_fullStr | To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure |
| title_full_unstemmed | To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure |
| title_short | To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure |
| title_sort | to mras treatment or not evidence from a meta analysis of randomized controlled trials of different mras on cardiovascular health in heart failure |
| topic | heart failure mineralocorticoid receptor antagonists all-cause mortality cardiovascular death meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1564860/full |
| work_keys_str_mv | AT jinyuhe tomrastreatmentornotevidencefromametaanalysisofrandomizedcontrolledtrialsofdifferentmrasoncardiovascularhealthinheartfailure AT gangchen tomrastreatmentornotevidencefromametaanalysisofrandomizedcontrolledtrialsofdifferentmrasoncardiovascularhealthinheartfailure AT yujiahuo tomrastreatmentornotevidencefromametaanalysisofrandomizedcontrolledtrialsofdifferentmrasoncardiovascularhealthinheartfailure AT chunyuzhang tomrastreatmentornotevidencefromametaanalysisofrandomizedcontrolledtrialsofdifferentmrasoncardiovascularhealthinheartfailure AT haojiexue tomrastreatmentornotevidencefromametaanalysisofrandomizedcontrolledtrialsofdifferentmrasoncardiovascularhealthinheartfailure AT jingwang tomrastreatmentornotevidencefromametaanalysisofrandomizedcontrolledtrialsofdifferentmrasoncardiovascularhealthinheartfailure AT yizhong tomrastreatmentornotevidencefromametaanalysisofrandomizedcontrolledtrialsofdifferentmrasoncardiovascularhealthinheartfailure AT juanxiao tomrastreatmentornotevidencefromametaanalysisofrandomizedcontrolledtrialsofdifferentmrasoncardiovascularhealthinheartfailure AT hongpingshen tomrastreatmentornotevidencefromametaanalysisofrandomizedcontrolledtrialsofdifferentmrasoncardiovascularhealthinheartfailure AT jianfeng tomrastreatmentornotevidencefromametaanalysisofrandomizedcontrolledtrialsofdifferentmrasoncardiovascularhealthinheartfailure AT jianfeng tomrastreatmentornotevidencefromametaanalysisofrandomizedcontrolledtrialsofdifferentmrasoncardiovascularhealthinheartfailure |